People · Operator
Named in public records as an officer, director or promoter · active 2017–2018 · Biotechnology, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Cydan II, Inc. | — | Biotechnology | Series A | $10.7M | $385.6M | 2017 |
| Tiburio Therapeutics Inc. | — | Pharmaceuticals | Series A | $5.0M | $154.9M | 2018 |
Sandip Kirstine Agarwala at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Sandip Kirstine Agarwala on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Mette Kirstine Agger | 2 | 6 |
| Christoph M. Adams | 2 | 4 |
| David M. Mott | 1 | 4 |
| James G. McArthur | 1 | 2 |
| Sara M. Nayeem | 1 | 2 |
| James M. McArthur | 1 | 2 |
| Sara Kirstine Nayeem | 1 | 2 |
| David Kirstine Mott | 1 | 2 |
| Abraham N. Ceesay | 1 | 1 |
| Barbara M. Dalton | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.